Survival of thalassemic patients referred to the Boo Ali Sina Teaching Hospital, Sari, Iran

Hemoglobin

Volumn 31, Issue 4, 2007, Pages 453-462

  Kosaryan, Mehrnoosh ^a   Vahidshahi, Koorosh ^a   Karami, Hosein ^a   Forootan, Morteza Alizadeh ^a   Ahangari, Mehdi ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Iran; Kaplan Meier; Survival; Transfusion dependent thalassemia (thal)

Indexed keywords

ACETYLSALICYLIC ACID; CALCITRIOL; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; DIGOXIN; ETHINYLESTRADIOL; HYDROXYUREA; IRON CHELATING AGENT; LEVOTHYROXINE; MEDROXYPROGESTERONE ACETATE; PENICILLIN G; TESTOSTERONE ENANTATE;

ADOLESCENT; ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CARDIOMYOPATHY; CHELATION; CHILD; COHORT ANALYSIS; CONFIDENCE INTERVAL; DEATH; DIABETES MELLITUS; DRUG FATALITY; FEMALE; HEART DISEASE; HUMAN; HYPOPARATHYROIDISM; IRAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT COMPLIANCE; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL; SURVIVAL RATE; TEACHING HOSPITAL; THROMBOCYTOSIS; TIME SERIES ANALYSIS; VALIDITY;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CARDIOMYOPATHIES; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; DIABETES COMPLICATIONS; HOSPITALS, TEACHING; HUMANS; IRAN; IRON CHELATING AGENTS; MIDDLE AGED; RISK FACTORS; SPLENECTOMY; SURVIVAL ANALYSIS;

EID: 36248962235     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1080/03630260701641294     Document Type: Article

References (24)

1. Borgna-Pignatti C, Rugolotto S, DeStefano P, Piga A, Di Gregorio F, Gamberine MR. Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998; 850:227-231.
2. Borgna-Pignatti C, Rugolotto S, DeStefano P. Survival and complications in patients with thalassaemia major treated with transfusion and deferoxamine. Haematologica 2004; 89(10):1187-1193.
3. Modell B, Letsky EA, Flynn DM, Peto R, Weatherall DJ. Survival and desferrioxamine in thalassaemia major. BMJ 1982; 284(6322):1081-1084.
4. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994; 331(9):574-577.
5. Ward A, Caro JJ, Green TC, Huybrechts K, Arana A, Wait S, Eleftheriou A An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol 2002; 2:3.
6. Samavat A, Modell B. Iranian national thalassaemia screening programme. BMJ 2004; 329(7475):1134-1137.
7. Management and Programming Organization of Mazandaran Population Statistics of Mazandaran Province, 1956-2000. Sari: Mazandaran Medical University. 2000; 63.
8. Pearson HA, Cohen AR, Giardina PJ, Kazazian HH. The changing profile of homozygous β-thalassemia demography and age distribution of current North America patients and changes in two decades. Pediatrics 1996; 97(3):352-356.
9. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK. Data from the UK Thalassaemia Registry. Lancet 2000; 355(9220):2051-2052.
10. Thalassaemia International Federation. Guideline for the clinical management of thalassaemia. TIF Publication, Cyprus 2000; 9-27.
11. Rahman M, Lodhi Y. Prospects and future of conservative managment of β thalassaemia major in a developing country. Pak J Med Sci 2004; 20(2):105-112.
12. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S. Survival and causes of death in thalassaemia major. Lancet 1989; 2(8653):27-30.
13. Yavarian M, Farshidfar GR, Karimi M, Almoazzez M, Harteveld CL, Giordano PC. Survival analysis of transfusion dependent β thalassemia major patients in the Iranian Province of Hormozgan. Ph.D. Thesis, Leiden University, Leiden, The Netherlands, 2005. ISBN: 90-9018926-2.
14. Kosaryan M. The picture of thalassemia in Islamic Republic of Iran. Proceedings of the 5th International Conference on Thalassemia and Hemoglobinopathies, Nicosia, Cyprus, April 1993, Abstract 89.
15. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
16. Olivieri NF, McGee A, Liu P, Korea G, Freedman MH, Benson L. Cardiac disease-free survival in patients with thalassemia major treated with subcutaneous desferrioxamine: an update on the Toronto cohort. Ann NY Acad Sci 1990; 612:585-586.
17. Reshidighader F, Kosaryan M, Farzin D, Afshin R. The effect of high dose intravenous Desferal on cardiac function of thalassemia major patients. J Mazandaran Univ Med Sci 2005; 47(15):6-13.
18. Ghaemian A, Hoseini A, Kosaryan M, Maanavifar R. Left ventricular diastolic abnormalities in β thalassemia major with normal systolic function. Med J Islamic Repub Iran 2002; 16(1):50-58.
19. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998; 103(2):361-364.
20. Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, Drakaki K, Kaloumenou I, Galani A, Kattamis Ch. Iron chelation treatment with combined therapy with deferiprone and deferoxamine : a 12-month trial. Blood Cells Mol Dis 2006; 36(1):21-25.
21. Link G, Konijin AM, Beuer W, Cabantchik ZI, Hershko C. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment on hypertransfused rats with labeled iron stores and iron-loaded rat heart cells in culture. J Lab Clin Med 2001; 138(2):130-138.
22. Telfer PT, Prescott E, Holden S Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000; 110(4):971-977.
23. Gamberini MR, Fortini M, gilli G, Testa MR, De Sanctis V. Epidemiology and chelation therapy effects on glucose homeostasis in thalassemia patients. J Pediatr Endocrinol Metab 1998; 11(Suppl 3):867-869.
24. Piga A, Galioti C, Fogliacco E, Tricta F. Comparative effect of deferiprone and deferoxamine on survival and cardiac disease in patient with thalassaemia major: a retrospective analysis. Haematologica 2003; 88(5):489-496.